


# Pharmaceutical Cost Reports

Fully Insured Individual and Group Coverage  
(Excludes self-funded insured health groups)


## 2020 Q3 RX Summary by Generic, Brand, and Over the Counter

	Count	Percent Of Claims	Allowed Amt	% of Dollar Volume
Generic	4,518,528	78%	\$ 102,286,219.89	13%
Brand	1,230,389	21%	\$ 659,658,105.27	86%
OTC	47,123	1%	\$ 3,307,476.65	0%
	5,796,040		\$ 765,251,801.81	

Percent of Claims



Percent of Dollar Volume



## 2020 Q3 Top 10 Drug Categories

Drug Category	Charged	Allowed	Paid	Member Responsibility
Diabetic Therapies	\$ 118,368,908.74	\$ 89,993,045.27	\$ 80,470,458.78	\$ 9,425,881.11
Therapies for: Transplant Rejection, Arthritis, Autoimmune Diseases	\$ 104,330,614.64	\$ 81,743,940.47	\$ 78,222,034.61	\$ 3,211,461.60
Cancer Therapies	\$ 46,829,864.22	\$ 31,614,894.59	\$ 30,059,961.18	\$ 1,516,446.79
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 37,705,331.73	\$ 26,205,624.60	\$ 22,633,193.48	\$ 3,528,945.84
Asthma/Breathing Therapies	\$ 28,295,132.48	\$ 21,347,814.73	\$ 17,273,565.10	\$ 4,034,729.55
Therapies for: Alcohol Dependence, ADHD/Mental Alertness, Appetite Suppression, Neuromuscular Abnormalities, Glaucoma, Increase Bladder/Intestinal Functions	\$ 27,766,859.69	\$ 18,108,278.05	\$ 14,032,462.27	\$ 4,059,285.44
Therapies for: Fertility, Contraceptives, Anemia, Osteoporosis, Weight Loss, Excessive Hair Growth, Uterine Bleeding, Hormone-Dependent Tumors	\$ 23,350,217.42	\$ 15,209,408.93	\$ 12,219,726.37	\$ 3,012,382.93
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 17,614,039.21	\$ 14,322,328.79	\$ 13,494,248.78	\$ 590,215.02
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 19,205,320.04	\$ 14,021,709.84	\$ 11,807,192.66	\$ 2,209,057.78
Pain Therapies	\$ 32,492,653.83	\$ 10,706,429.04	\$ 8,176,029.16	\$ 2,526,650.94

**2020 Q3 Top 30 Drugs by Average Dollar Volume \***

<b>Trade Name</b>	<b>RX Type</b>	<b>Average Day Supply</b>	<b>Average Charged</b>	<b>Average Allowed</b>	<b>Average Paid</b>	<b>Average Member Responsibility</b>
HEMLIBRA	BRAND	27	\$ 70,435.48	\$ 59,151.72	\$ 57,324.75	\$ 435.70
HAEGARDA C1 ESTERASE INHIBITOR SUBCUTANEOUS HUMAN	BRAND	28	\$ 79,717.95	\$ 57,130.78	\$ 56,730.47	\$ 400.31
KORLYM	BRAND	30	\$ 43,509.19	\$ 43,509.19	\$ 43,289.19	\$ 220.00
GATTEX	BRAND	30	\$ 113,765.79	\$ 41,805.97	\$ 41,452.47	\$ 353.50
TAKHZYRO	BRAND	24	\$ 71,609.03	\$ 40,038.28	\$ 40,020.78	\$ 17.50
PROCYSBI	BRAND	30	\$ 37,165.70	\$ 32,423.43	\$ 32,012.37	\$ 411.06
HARVONI	BRAND	28	\$ 34,253.56	\$ 27,312.69	\$ 24,958.56	\$ 2,354.13
KALYDECO	BRAND	28	\$ 29,026.36	\$ 24,007.63	\$ 23,919.75	\$ 87.88
TRIKAFTA	BRAND	27	\$ 28,820.72	\$ 23,703.92	\$ 23,263.76	\$ 432.04
ORENITRAM	BRAND	28	\$ 40,840.80	\$ 23,143.11	\$ 22,982.17	\$ 160.94
SYMDEKO	BRAND	28	\$ 27,051.52	\$ 21,763.20	\$ 21,223.25	\$ 537.65
ORKAMBI	BRAND	28	\$ 25,103.08	\$ 21,231.99	\$ 20,776.66	\$ 444.65
STELARA	BRAND	39	\$ 24,745.44	\$ 20,464.93	\$ 20,008.47	\$ 416.19
EPCLUSA	BRAND	28	\$ 25,904.80	\$ 21,093.80	\$ 19,873.00	\$ 1,294.46
PALYNZIQ	BRAND	29	\$ 23,194.50	\$ 20,457.79	\$ 19,778.64	\$ 679.16
UPTRAVI	BRAND	29	\$ 36,318.32	\$ 20,041.75	\$ 19,526.10	\$ 515.66
VYNDAMAX	BRAND	30	\$ 23,871.38	\$ 18,973.88	\$ 18,811.80	\$ 162.08
POMALYST	BRAND	27	\$ 21,943.95	\$ 18,210.09	\$ 17,921.75	\$ 288.33
HETLIOZ	BRAND	30	\$ 19,982.13	\$ 17,330.81	\$ 17,202.91	\$ 127.90
CABOMETYX	BRAND	25	\$ 20,592.86	\$ 17,053.07	\$ 16,707.93	\$ 345.14
LENVIMA	BRAND	26	\$ 26,720.13	\$ 16,178.54	\$ 16,091.64	\$ 86.90
REVLIMID	BRAND	26	\$ 19,005.04	\$ 15,740.85	\$ 15,613.55	\$ 127.31
SKYRIZI	BRAND	40	\$ 19,848.02	\$ 16,393.25	\$ 15,592.23	\$ 778.05
TAGRISSO	BRAND	30	\$ 20,119.29	\$ 15,542.84	\$ 15,439.13	\$ 103.71
AFINITOR	BRAND	26	\$ 18,069.44	\$ 15,332.69	\$ 14,753.07	\$ 579.62
JYNARQUE	BRAND	27	\$ 18,007.67	\$ 14,435.17	\$ 14,180.14	\$ 247.94
KUVAN	BRAND	30	\$ 16,778.72	\$ 14,491.46	\$ 14,102.45	\$ 389.01
XYREM	BRAND	28	\$ 15,638.87	\$ 14,155.75	\$ 13,831.64	\$ 324.11

ALECENSA	BRAND	26	\$ 17,113.27	\$ 13,523.40	\$ 13,481.25	\$ 42.15
RUBRACA	BRAND	29	\$ 23,721.88	\$ 13,232.78	\$ 13,232.78	\$ -

\*To be included in this table, at least 20 prescriptions for the drug must exist in the database.

**2020 Q3 Top 30 Drugs by Total Dollar Volume \***

<b>TradeName</b>	<b>RX Type</b>	<b>Total Charged</b>	<b>Total Allowed</b>	<b>Total Paid</b>	<b>Total Member Responsibility</b>
HUMIRA	BRAND	\$ 78,876,077.40	\$ 63,590,844.22	\$ 60,217,536.10	\$ 3,076,810.17
STELARA	BRAND	\$ 34,495,148.18	\$ 28,528,105.81	\$ 27,891,803.33	\$ 580,175.46
ATORVASTATIN CALCIUM	GENERIC	\$ 27,393,822.59	\$ 1,219,619.05	\$ 438,134.50	\$ 782,982.91
ENBREL	BRAND	\$ 23,395,261.00	\$ 18,979,358.77	\$ 17,863,572.76	\$ 1,115,786.01
NOVOLOG	BRAND	\$ 17,789,504.53	\$ 14,016,824.65	\$ 12,947,327.37	\$ 1,027,982.91
TRULICITY	BRAND	\$ 16,700,706.10	\$ 13,196,728.37	\$ 12,059,365.48	\$ 1,124,550.94
OZEMPIC	BRAND	\$ 16,363,294.29	\$ 12,973,429.11	\$ 11,933,587.45	\$ 1,036,913.92
NORDITROPIN	BRAND	\$ 15,970,040.70	\$ 12,385,431.34	\$ 11,755,858.36	\$ 610,925.58
TRIKAFTA	BRAND	\$ 15,476,726.50	\$ 12,729,007.60	\$ 12,492,640.71	\$ 232,006.89
OMEPRAZOLE	GENERIC	\$ 14,618,500.27	\$ 652,009.00	\$ 78,499.83	\$ 574,087.93
VYVANSE	BRAND	\$ 14,552,271.79	\$ 11,505,001.35	\$ 8,892,280.06	\$ 2,604,009.68
OTEZLA	BRAND	\$ 13,949,638.45	\$ 11,343,206.43	\$ 10,273,696.01	\$ 1,009,110.63
COSENTYX	BRAND	\$ 13,893,021.78	\$ 10,851,633.64	\$ 10,201,542.49	\$ 580,771.99
ARIPIRAZOLE	GENERIC	\$ 12,997,132.42	\$ 376,573.64	\$ 170,814.50	\$ 205,828.39
VICTOZA	BRAND	\$ 12,575,987.51	\$ 9,878,981.73	\$ 9,249,259.22	\$ 613,306.18
ROSUVASTATIN CALCIUM	GENERIC	\$ 11,066,641.90	\$ 478,775.70	\$ 207,439.05	\$ 272,053.78
JARDIANCE	BRAND	\$ 10,373,249.93	\$ 8,198,245.22	\$ 7,183,987.96	\$ 1,010,419.81
DUPIXENT	BRAND	\$ 9,841,380.43	\$ 7,823,495.40	\$ 6,863,170.35	\$ 829,210.12
TRESIBA	BRAND	\$ 9,808,134.28	\$ 7,669,872.60	\$ 6,949,630.45	\$ 718,387.08
PANTOPRAZOLE SODIUM	GENERIC	\$ 9,735,719.91	\$ 501,770.72	\$ 74,570.07	\$ 427,638.94
ELIQUIS	BRAND	\$ 9,453,580.62	\$ 7,449,552.27	\$ 6,284,311.97	\$ 1,163,253.09
BIKTARVY	BRAND	\$ 9,266,829.57	\$ 7,606,586.39	\$ 6,509,992.32	\$ 1,096,494.61
TECFIDERA	BRAND	\$ 8,513,926.49	\$ 6,895,491.03	\$ 6,576,070.55	\$ 296,154.30
VENLAFAXINE HYDROCHLORIDE	GENERIC	\$ 8,025,224.35	\$ 1,144,035.76	\$ 553,813.72	\$ 589,868.94
JANUVIA	BRAND	\$ 7,927,092.80	\$ 6,187,834.80	\$ 5,499,580.67	\$ 688,279.76
REVLIMID	BRAND	\$ 7,659,031.09	\$ 6,343,563.92	\$ 6,292,259.61	\$ 51,304.31
XARELTO	BRAND	\$ 7,576,457.15	\$ 5,954,651.29	\$ 5,065,855.01	\$ 885,347.91

SYMBICORT	BRAND	\$ 7,569,358.53	\$ 5,921,183.94	\$ 4,643,752.68	\$ 1,276,725.19
MONTELUKAST SODIUM	GENERIC	\$ 7,566,968.64	\$ 426,809.52	\$ 101,789.48	\$ 325,491.20
ONDANSETRON	GENERIC	\$ 7,556,356.11	\$ 260,759.10	\$ 72,932.56	\$ 188,785.33

\* To be included in this table, at least 20 prescriptions for the drug must exist in the database.

## 2020 Q3 RX Counts by Plan / Product Type

Plan Type	Plan Description	Product Type	Product Description	RXcount	Charged Per Script	Allowed Per Script	Paid Per Script	Mbr Resp Per Script
2	PPO	1	Medical/Health	3,895,734	\$ 296.72	\$ 160.43	\$ 141.02	\$ 19.06
7	Qualified High Deductible PI	1	Medical/Health	762,302	\$ 337.82	\$ 183.46	\$ 136.35	\$ 46.61
4	POS	1	Medical/Health	367,028	\$ 293.91	\$ 157.31	\$ 140.15	\$ 17.17
3	HMO	1	Medical/Health	61,306	\$ 481.40	\$ 248.46	\$ 224.94	\$ 23.57
7	Qualified High Deductible PI	2	Ancillary Drug	31	\$ 215.90	\$ 110.10	\$ 88.51	\$ 22.52
4	POS	2	Ancillary Drug	1	\$ 10.84	\$ 5.89	\$ -	\$ 5.89

## 2020 Q3 PMPM RX Costs

	Member Months	Allowed	Average PMPM
Age <= 14	746,832	\$ 43,214,843.47	\$ 57.86
Age 15-24	652,544	\$ 72,295,580.06	\$ 110.79
Age 25-44	1,448,168	\$ 216,359,496.31	\$ 149.40
Age 45-64	1,496,679	\$ 440,192,828.29	\$ 294.11

## Average Allowed Charge PMPM by Age Group

